Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Internal Medicine

Ophthalmology

Pediatrics

Molecular Biology

Show all topics

DOI

10.1016/s0140-6736(17)31868-8

Other Formats

PDF